Patents by Inventor Eric Thomas Baldwin

Eric Thomas Baldwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-BCMA antibodies and uses thereof
    Patent number: 10072088
    Abstract: Provided herein are antibodies that immunospecifically bind to BCMA. Also described are related polynucleotides capable of encoding the provided BCMA-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor BCMA-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with BCMA-expressing cancer and thus may be amenable to treatment with a BCMA-specific anti-cancer therapeutic, such as the multispecific antibodies against BCMA and CD3 described herein.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: September 11, 2018
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Kodandaram Pillarisetti, Eric Thomas Baldwin, Gordon D. Powers, Rosa Maria Fernandes Cardoso, Ricardo Attar, Francois Gaudet
  • Anti-BCMA Antibodies, Bispecific Antigen Binding Molecules that Bind BCMA and CD3, and Uses Thereof
    Publication number: 20170051068
    Abstract: Provided herein are antibodies that immunospecifically bind to BCMA. Also described are related polynucleotides capable of encoding the provided BCMA-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor BCMA-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with BCMA-expressing cancer and thus may be amenable to treatment with a BCMA-specific anti-cancer therapeutic, such as the multispecific antibodies against BCMA and CD3 described herein.
    Type: Application
    Filed: August 16, 2016
    Publication date: February 23, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Kodandaram Pillarisetti, Eric Thomas Baldwin, Gordon D. Powers, Rosa Maria Fernandes Cardoso, Ricardo Attar, Francois Gaudet